4.6 Article

Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study

Journal

BMC CANCER
Volume 15, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12885-015-1821-9

Keywords

Endometriosis; Ovarian cancer; Endometrial cancer; Risk factor

Categories

Funding

  1. Deutsche Forschungsgemeinschaft
  2. Friedrich-Alexander-Universitat Erlangen-Numberg (FAU) within the funding programme Open Access Publishing

Ask authors/readers for more resources

Background: No screening programs are available for ovarian or endometrial cancer. One reason for this is the low incidence of the conditions, resulting in low positive predictive values for tests, which are not very specific. One way of addressing this problem might be to use risk factors to define subpopulations with a higher incidence. The aim of this study was to investigate the extent to which a medical history of endometriosis can serve as a risk factor for ovarian or endometrial cancer. Methods: In a hospital-based case-control analysis, the cases represented patients with endometrial or ovarian cancer who were participating in studies aimed at assessing the risk for these diseases. The controls were women between the age of 40 and 85 who were invited to take part via a newspaper advertisement. A total of 289 cases and 1016 controls were included. Using logistic regression models, it was tested whether self-reported endometriosis is a predictor of case-control status in addition to age, body mass index (BMI), number of pregnancies and previous oral contraceptive (OC) use. Results: Endometriosis was reported in 2.1 % of the controls (n = 21) and 4.8 % of the cases (n = 14). Endometriosis was a relevant predictor for case-control status in addition to other predictive factors (OR 2.63; 95 % CI, 1.28 to 5.41). Conclusion: This case-control study found that self-reported endometriosis may be a risk factor for endometrial or ovarian cancer in women between 40 and 85 years. There have been very few studies addressing this issue, and incorporating it into a clinical prediction model would require a more precise characterization of the risk factor of endometriosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Ashley Weir, Eun-Young Kang, Nicola S. Meagher, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Aleksandra Gentry-Maharaj, Andy Ryan, Naveena Singh, Martin Widschwendter, Jennifer Alsop, Michael S. Anglesio, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Jessica Boros, Alison H. Brand, James D. Brenton, Angela Brooks-Wilson, Michael E. Carney, Julie M. Cunningham, Kara L. Cushing-Haugen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Sian Fereday, Anna Fischer, Luis Paz-Ares, Javier Gayarre, Blake C. Gilks, Marcel Grube, Paul R. Harnett, Holly R. Harris, Arndt Hartmann, Alexander Hein, Joy Hendley, Brenda Y. Hernandez, Sabine Heublein, Yajue Huang, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez-Linan, Catherine J. Kennedy, Felix K. F. Kommoss, Jennifer M. Koziak, Bernhard Kraemer, Nhu D. Le, Jaime Lesnock, Jenny Lester, Jan Lubinski, Janusz Menkiszak, Britta Ney, Alexander Olawaiye, Sandra Orsulic, Ana Osorio, Luis Robles-Diaz, Matthias Ruebner, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Helen Steed, Aline Talhouk, Sarah E. Taylor, Nadia Traficante, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Javier Benitez, Andrew Berchuck, David D. Bowtell, Francisco J. Candido dos Reis, Linda S. Cook, Anna DeFazio, Jennifer A. Doherty, Peter A. Fasching, Maria J. Garcia, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, David G. Huntsman, Beth Y. Karlan, Stefan Kommoss, Francesmary Modugno, Joellen M. Schildkraut, Hans-Peter Sinn, Annette Staebler, Linda E. Kelemen, Caroline E. Ford, Usha Menon, Paul D. P. Pharoah, Martin Koebel, Susan J. Ramus, D. Bowtell, A. DeFazio, N. Traficante, S. Fereday, A. Brand, P. Harnett, R. Sharma

Summary: Recently, a study found a positive correlation between protein expression of FOXJ1 and the 5-year survival rate of patients with tubo-ovarian high-grade serous carcinoma (HGSC). However, protein expression of GMNN was not significantly associated with patient survival. This study provides preliminary evidence for the prognostic value of FOXJ1 in HGSC and validates the prior mRNA-based prognostic association through immunohistochemistry.

BRITISH JOURNAL OF CANCER (2023)

Article Psychology, Developmental

Deactivating attachment strategies associate with early processing of facial emotion and familiarity in middle childhood: an ERP study

Melanie Kungl, Pascal Vrticka, Christine Heinisch, Matthias W. Beckmann, Peter A. Fasching, Clara Ziegler, Gottfried Spangler

Summary: Neurophysiological evidence suggests a link between attachment and the neural processing of emotion expressions. This study examines this relationship in middle childhood and investigates the impact of facial familiarity. The results show that attachment deactivation is associated with increased vigilance towards angry faces, while no effect of hyperactivation is found.

ATTACHMENT & HUMAN DEVELOPMENT (2023)

Article Medicine, Research & Experimental

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

Min Huang, Peter A. Fasching, Amin Haiderali, Weiguang Xue, Chelsey Yang, Wilbur Pan, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Joyce O'Shaughnessy

Summary: This study evaluated the cost-effectiveness of adding pembrolizumab to neoadjuvant chemotherapy and continuing it as a single-agent adjuvant treatment for high-risk eTNBC in the USA. The results showed that pembrolizumab in combination with chemotherapy is a cost-effective option for these patients.

ADVANCES IN THERAPY (2023)

Article Oncology

Return of individual genomic research results within the PRAEGNANT multicenter registry study

Hanna Huebner, Matthias Ruebner, Christian Kurbacher, Peyman Hadji, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Sabrina Uhrig, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Haeberle, Diana Lueftner, Markus Wallwiener, Volkmar Mueller, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Michael Untch, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl, Peter A. Fasching, Laura L. Michel

Summary: The PRAEGNANT study is a registry study that analyzed genetic alterations in 37 breast cancer predisposition genes for 396 metastatic breast cancer patients. The study aimed to return genetic results to physicians and evaluate the impact on treatment decisions and patients' quality of life. Evaluation of the study scored 7 out of 10.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Article Oncology

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Eun-Young Kang, Ashley Weir, Nicola S. Meagher, Kyo Farrington, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S. Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Hans Boesmueller, Jessica Boros, Alison H. Brand, Angela Brooks-Wilson, Sara Y. Brucker, Michael E. Carney, Yovanni Casablanca, Alicia Cazorla-Jimenez, Paul A. Cohen, Thomas P. Conrads, Linda S. Cook, Penny Coulson, Madeleine Courtney-Brooks, Daniel W. Cramer, Philip Crowe, Julie M. Cunningham, Cezary Cybulski, Kathleen M. Darcy, Mona A. El-Bahrawy, Esther Elishaev, Ramona Erber, Rhonda Farrell, Sian Fereday, Anna Fischer, Maria J. Garcia, Simon A. Gayther, Aleksandra Gentry-Maharaj, C. Blake Gilks, Marcel Grube, Paul R. Harnett, Shariska Petersen Harrington, Philipp Harter, Arndt Hartmann, Jonathan L. Hecht, Sebastian Heikaus, Alexander Hein, Florian Heitz, Joy Hendley, Brenda Y. Hernandez, Susanna Hernando Polo, Sabine Heublein, Akira Hirasawa, Estrid Hogdall, Claus K. Hogdall, Hugo M. Horlings, David G. Huntsman, Tomasz Huzarski, Andrea Jewell, Mercedes Jimenez-Linan, Michael E. Jones, Scott H. Kaufmann, Catherine J. Kennedy, Dineo Khabele, Felix K. F. Kommoss, Roy F. P. M. Kruitwagen, Diether Lambrechts, Nhu D. Le, Marcin Lener, Jenny Lester, Yee Leung, Anna Linder, Liselore Loverix, Jan Lubinski, Rashna Madan, G. Larry Maxwell, Francesmary Modugno, Susan L. Neuhausen, Alexander Olawaiye, Siel Olbrecht, Sandra Orsulic, Jose Palacios, Celeste Leigh Pearce, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Cristina Rodriguez-Antona, Matthias Ruebner, Andy Ryan, Stuart G. Salfinger, Naoko Sasamoto, Joellen M. Schildkraut, Minouk J. Schoemaker, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Naveena Singh, Gabe S. Sonke, Linda Steele, Colin J. R. Stewart, Karin Sundfeldt, Anthony J. Swerdlow, Aline Talhouk, Adeline Tan, Sarah E. Taylor, Kathryn L. Terry, Aleksandra Toloczko, Nadia Traficante, Koen K. Van de Vijver, Maaike A. van der Aa, Toon Van Gorp, Els Van Nieuwenhuysen, Lilian Van-Wagensveld, Ignace Vergote, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Anna H. Wu, Javier Benitez, Andrew Berchuck, Francisco J. Candido Dos Reis, Anna DeFazio, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Beth Y. Karlan, Stefan Kommoss, Usha Menon, Hans-Peter Sinn, Annette Staebler, James D. Brenton, David D. Bowtell, Paul D. P. Pharoah, Susan J. Ramus, Martin Kobel

Summary: This study validates that high-level amplification of CCNE1 is associated with shorter survival in tubo-ovarian high-grade serous carcinoma (HGSC), supporting its use as a prognostic biomarker in this disease.

CANCER (2023)

Article Oncology

Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer- A single-arm phase II trial (NeoImmunoboost, AGO-B-041)

Peter A. Fasching, Alexander Hein, Hans-Christian Kolberg, Lothar Haeberle, Sabrina Uhrig, Matthias Ruebner, Erik Belleville, Carolin C. Hack, Tanja N. Fehm, Wolfang Janni, Arndt Hartmann, Ramona Erber, Anna-Katharin Theuser, Sara Y. Brucker, Andreas D. Hartkopf, Michael Untch

Summary: This study investigated the efficacy of nP-containing neoadjuvant chemotherapy in combination with pembrolizumab for breast cancer patients. The results showed a high pathological complete response rate and acceptable side effects.

EUROPEAN JOURNAL OF CANCER (2023)

Article Biochemistry & Molecular Biology

FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

Gisella Figlioli, Amandine Billaud, Thomas U. Ahearn, Natalia N. Antonenkova, Heiko Becher, Matthias W. Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, Marinus J. Blok, Natalia Bogdanova, Bernardo Bonanni, Barbara Burwinkel, Nicola J. Camp, Archie Campbell, Jose E. Castelao, Melissa H. Cessna, Stephen J. Chanock, Kamila Czene, Peter Devilee, Thilo Doerk, Christoph Engel, Mikael Eriksson, Peter A. Fasching, Jonine D. Figueroa, Marike Gabrielson, Manuela Gago-Dominguez, Montserrat Garcia-Closas, Anna Gonzalez-Neira, Felix Grassmann, Pascal Guenel, Melanie Gundert, Andreas Hadjisavvas, Eric Hahnen, Per Hall, Ute Hamann, Patricia A. Harrington, Wei He, Peter Hillemanns, Antoinette Hollestelle, Maartje J. Hooning, Reiner Hoppe, Anthony Howell, Keith Humphreys, Agnes Jager, Anna Jakubowska, Elza K. Khusnutdinova, Yon-Dschun Ko, Vessela N. Kristensen, Annika Lindblom, Jolanta Lissowska, Jan Lubinski, Arto Mannermaa, Siranoush Manoukian, Sara Margolin, Dimitrios Mavroudis, William G. Newman, Nadia Obi, Mihalis Panayiotidis, Muhammad U. Rashid, Valerie Rhenius, Matti A. Rookus, Emmanouil Saloustros, Elinor J. Sawyer, Rita K. Schmutzler, Mitul Shah, Reijo Sironen, Melissa C. Southey, Maija Suvanto, Rob A. E. M. Tollenaar, Ian Tomlinson, Therese Truong, Lizet E. van der Kolk, Elke M. van Veen, Barbara Wappenschmidt, Xiaohong R. Yang, Manjeet K. Bolla, Joe Dennis, Alison M. Dunning, Douglas F. Easton, Michael Lush, Kyriaki Michailidou, Paul D. P. Pharoah, Qin Wang, Muriel A. Adank, Marjanka K. Schmidt, Irene L. Andrulis, Jenny Chang-Claude, Heli Nevanlinna, Georgia Chenevix-Trench, D. Gareth Evans, Roger L. Milne, Paolo Radice, Paolo Peterlongo

Summary: Evidence from the BRIDGES study suggests that germline protein truncating variants (PTVs) in FANCM are associated with increased risk of ER-negative and triple-negative breast cancer (TNBC), particularly for those with a family history. This study further investigates the association between FANCM missense variants (MVs) and breast cancer risk using the BRIDGES study, analyzing a total of 689 MVs. The results indicate that FANCM MVs may be low/moderate risk factors for ER-negative and TNBC subtypes of breast cancer.

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Article Oncology

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar

Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

Zhuxuan Fu, Maria Mori Brooks, Sarah Irvin, Susan Jordan, Katja K. H. Aben, Hoda Anton-Culver, Elisa Bandera, Matthias W. Beckmann, Andrew Berchuck, Angela Brooks-Wilson, Jenny Chang-Claude, Linda S. Cook, Daniel W. Cramer, Kara L. Cushing-Haugen, Jennifer A. Doherty, Arif B. Ekici, Peter A. Fasching, Renee T. Fortner, Simon A. Gayther, Aleksandra Gentry-Maharaj, Graham G. Giles, Ellen L. Goode, Marc T. Goodman, Holly R. Harris, Alexander Hein, Rudolf Kaaks, Lambertus A. Kiemeney, Martin Koebel, Joanne Kotsopoulos, Nhu D. Le, Alice W. Lee, Keitaro Matsuo, Valerie McGuire, John R. McLaughlin, Usha Menon, Roger L. Milne, Kirsten B. Moysich, Celeste Leigh Pearce, Malcolm C. Pike, Bo Qin, Susan J. Ramus, Marjorie J. Riggan, Joseph H. Rothstein, Joellen M. Schildkraut, Weiva Sieh, Rebecca Sutphen, Kathryn L. Terry, Pamela J. Thompson, Linda Titus, Anne M. van Altena, Emily White, Alice S. Whittemore, Anna H. Wu, Wei Zheng, Argyrios Ziogas, Sarah E. Taylor, Lu Tang, Thomas Songer, Nicolas Wentzensen, Penelope M. Webb, Harvey A. Risch, Francesmary Modugno

Summary: The lifetime ovulatory years (LOY) are positively associated with nonmucinous epithelial ovarian cancer (EOC) risk, implicating factors beyond ovulation in the development of EOC. The protective effects of parity and oral contraceptive use may not solely depend on anovulation.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Genetics & Heredity

Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

Stefanie H. Mueller, Alvina G. Lai, Maria Valkovskaya, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang, Joe Dennis, Michael Lush, Zomoruda Abu-Ful, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Volker Arndt, Kristan J. Aronson, Annelie Augustinsson, Thais Baert, Laura E. Beane Freeman, Matthias W. Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, Carl Blomqvist, Natalia Bogdanova, Stig E. Bojesen, Bernardo Bonanni, Hermann Brenner, Sara Y. Brucker, Saundra S. Buys, Jose E. Castelao, Tsun L. Chan, Jenny Chang-Claude, Stephen J. Chanock, Ji-Yeob Choi, Wendy K. Chung, Sarah Colonna, Sten Cornelissen, Fergus J. Couch, Kamila Czene, Mary B. Daly, Peter Devilee, Thilo Dork, Laure Dossus, Miriam Dwek, Diana M. Eccles, Arif B. Ekici, A. Heather Eliassen, Christoph Engel, D. Gareth Evans, Peter A. Fasching, Olivia Fletcher, Henrik Flyger, Manuela Gago-Dominguez, Yu-Tang Gao, Montserrat Garcia-Closas, Jose A. Garcia-Saenz, Jeanine Genkinger, Aleksandra Gentry-Maharaj, Felix Grassmann, Pascal Guenel, Melanie Gundert, Lothar Haeberle, Eric Hahnen, Christopher A. Haiman, Niclas Hakansson, Per Hall, Elaine F. Harkness, Patricia A. Harrington, Jaana M. Hartikainen, Mikael Hartman, Alexander Hein, Weang-Kee Ho, Maartje J. Hooning, Reiner Hoppe, John L. Hopper, Richard S. Houlston, Anthony Howell, David J. Hunter, Dezheng Huo, Abctb Investigators, Hidemi Ito, Motoki Iwasaki, Anna Jakubowska, Wolfgang Janni, Esther M. John, Michael E. Jones, Audrey Jung, Rudolf Kaaks, Daehee Kang, Elza K. Khusnutdinova, Sung-Won Kim, Cari M. Kitahara, Stella Koutros, Peter Kraft, Vessela N. Kristensen, Katerina Kubelka-Sabit, Allison W. Kurian, Ava Kwong, James Lacey, Diether Lambrechts, Loic Le Marchand, Jingmei Li, Martha Linet, Wing-Yee Lo, Jirong Long, Artitaya Lophatananon, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Keitaro Matsuo, Dimitrios Mavroudis, Usha Menon, Kenneth Muir, Rachel A. Murphy, Heli Nevanlinna, William G. Newman, Dieter Niederacher, Katie M. O'Brien, Nadia Obi, Kenneth Offit, Olufunmilayo Olopade, Andrew F. Olshan, Hakan Olsson, Sue K. Park, Alpa Patel, Achal Patel, Charles M. Perou, Julian Peto, Paul D. P. Pharoah, Dijana Plaseska-Karanfilska, Nadege Presneau, Brigitte Rack, Paolo Radice, Dhanya Ramachandran, Muhammad U. Rashid, Gad Rennert, Atocha Romero, Kathryn J. Ruddy, Matthias Ruebner, Emmanouil Saloustros, Dale P. Sandler, Elinor J. Sawyer, Marjanka K. Schmidt, Rita K. Schmutzler, Michael O. Schneider, Christopher Scott, Mitul Shah, Priyanka Sharma, Chen-Yang Shen, Xiao-Ou Shu, Jacques Simard, Harald Surowy, Rulla M. Tamimi, William J. Tapper, Jack A. Taylor, Soo Hwang Teo, Lauren R. Teras, Amanda E. Toland, Rob A. E. M. Tollenaar, Diana Torres, Gabriela Torres-Mejia, Melissa A. Troester, Therese Truong, Celine M. Vachon, Joseph Vijai, Clarice R. Weinberg, Camilla Wendt, Robert Winqvist, Alicja Wolk, Anna H. Wu, Taiki Yamaji, Xiaohong R. Yang, Jyh-Cherng Yu, Wei Zheng, Argyrios Ziogas, Elad Ziv, Alison M. Dunning, Douglas F. Easton, Harry Hemingway, Ute Hamann, Karoline B. Kuchenbaecker

Summary: This study identified 14 genes associated with breast cancer using gene-based aggregation analysis, including two newly discovered genes FMNL3 and AC058822.1. Furthermore, associations with established candidate genes like ESR1 were found through the collaboration of multi-ancestral cohorts, highlighting the importance of diversifying study cohorts. These findings provide new insights into the development of breast cancer.

GENOME MEDICINE (2023)

Article Medicine, General & Internal

Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis

Carla E. Schulmeyer, Peter A. Fasching, Lothar Haeberle, Julia Meyer, Michael Schneider, David Wachter, Matthias Ruebner, Patrik Poeschke, Matthias W. Beckmann, Arndt Hartmann, Ramona Erber, Paul Gass

Summary: The study evaluated the prognosis of patients with triple-negative breast cancer (TNBC) and other subtypes by using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). The results showed that the non-TBN subgroup of TNBC lesions with at least one positive biomarker (CK5, CD117, and/or EGFR) had longer disease-free survival (DFS) and overall survival (OS). This highlights the importance of molecular-based subclassifications of breast cancer for treatment options and prognosis stratification.

DIAGNOSTICS (2023)

Article Oncology

The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer

Raphela A. Ranjan, Julienne K. Muenzner, Philipp Kunze, Carol I. Geppert, Matthias Ruebner, Hanna Huebner, Peter A. Fasching, Matthias W. Beckmann, Tobias Baeuerle, Arndt Hartmann, Wolfgang Walther, Markus Eckstein, Ramona Erber, Regine Schneider-Stock

Summary: The biological and growth characteristics of two breast cancer cell lines were investigated in a CAM model, and the results confirmed the known features of the breast cancer cell lines observed in vitro and in cells. The CAM model was found to be a reliable alternative for breast cancer research, reducing the need for murine animal experiments.

CANCERS (2023)

Article Obstetrics & Gynecology

Genetic variants in the genes of the sex steroid hormone metabolism and depressive symptoms during and after pregnancy

Michael O. Schneider, Jutta Pretscher, Tamme W. Goecke, Lothar Haeberle, Anne Engel, Johannes Kornhuber, Anna Eichler, Arif B. Ekici, Matthias W. Beckmann, Peter A. Fasching, Eva Schwenke

Summary: This study did not find any association between the candidate haplotypes analyzed in PGR and CYP19A1 genes, as well as single SNPs in ESR1 and COMT genes, with depression scores assessed by EPDS in a cohort of healthy unselected pregnant women.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2023)

No Data Available